Micro RNA-98 interferes with expression interleukin-10 in peripheral B cells of patients with lung cancer

Abstract

Interleukin (IL)-10-producing B cells (B10 cells) plays an important role in the tumor tolerance. High frequency of peripheral B10 cell was reported in patients with lung cancer recently. Micro RNA (miR) regulates some gene expression. This study test a hypothesis that miR-98 suppresses the expression of IL-10 in B cells of subjects with lung cancer. The results showed that the levels of miR-98 were significantly less in peripheral B cells of patients with lung cancer than that in healthy subjects. IL-10 mRNA levels in peripheral B cells were significantly higher in lung cancer patients as compared with healthy controls. A negative correlation was identified between miR-98 and IL-10 in peripheral B cells. Serum IL-13 was higher in lung cancer patients than that in healthy controls. The levels of IL-13 were also negatively correlated with IL-10 in B cells. Exposure B10 cells to IL-13 in the culture or over expression of miR-98 reduced the expression of IL-10 in B cells. Administration with miR-98-laden liposomes inhibited the lung cancer growth in a mouse model. In conclusion, up regulation of miR-98 inhibits the expression of IL-10 in B cells, which may contribute to inhibit the lung cancer tolerance in the body.

Epigenetic Changes Associated With Interleukin-10

“…In addition, miRNA-98 is an important miRNA, which is associated with IL-10 in various diseases, such as HCC, Lung cancer, Myocarditis, etc. (61,62,71). These studies have shown that the epigenetic mechanism of IL-10 help us to have a deeper understanding of the occurrence and progression of the disease.…”

“…Serum miRNA-146a and miRNA-150 can be used as biomarkers for diagnosis and prediction of ALI (46), and rno-miRNA-30b-5p is a new therapeutic target for uveitis (59). It is worth noting that miRNA-98 can be involved in the treatment of various diseases, such as lung cancer, liver cancer and other tumors, as well as myocarditis and allergic diseases (61,62,64,71). In summary, regulatory miRNAs targeting IL-10 provide new therapeutic targets for many diseases, and also provide ideas for the development of new drugs for immune and inflammatory diseases in the future.…”

Immunosuppressive Mechanisms of Regulatory B Cells

“…Other cytokines and factors described as IL-10 + Breg inducers include IL-33 ( 142 , 143 ), granulocyte macrophage colony-stimulating factor (GM-CSF) ( 144 ), a GM-CSF/IL-15 fusokine ( 57 ), thymosin-α1 ( 145 ), human chorionic gonadotrophin ( 146 – 148 ), retinoic acid ( 149 ), hypoxia-inducible factor-1α ( 150 ), vitamin D3 ( 90 ), insulin-like growth factor 2 ( 151 ), and indoleamine 2,3 deoxygenase (IDO) ( 134 ). Conversely, IL-10 production by B cells has been determined to be repressed by several molecules such as soluble TNF ( 152 , 153 ), transforming growth factor (TGF)-β ( 70 , 126 , 127 ), IL-4 ( 154 , 155 ), IL-13 ( 156 – 158 ), IL-17 ( 159 ), lipoxin A4 ( 160 ), prostaglandin E2 ( 161 ), and progesterone and estradiol ( 162 ), although some results are divergent, likely due to different stimulation conditions or subpopulations assessed ( 163 , 164 ). In addition, IL-10 expression by B cells can be upregulated by neurotransmitters such as dopamine ( 165 ) and norepinephrine ( 166 ), as well as NMDA-receptor antagonists ( 167 ).…”

Role of microRNAs in COVID-19 with implications for therapeutics

“…2 ) [40] . Additionally, this small RNA is significantly less expressed in patients with lung cancer and its modulation leads to suppression of IL-10 in B cells and cancer growth inhibition [90] . Therefore, in patients with respiratory diseases targeting some miRNAs would be a suitable approach for treatment of COVID-19 as it can lead to relieving signs and symptoms of the illness as well as targeting SARS-CoV-2 infection.…”